Nowa wersja platformy jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2013 | 8 | 3 | 322-327
Tytuł artykułu

Malignancies after kidney transplantation: 3 clinical case reports

Treść / Zawartość
Warianty tytułu
Języki publikacji
Post-transplant malignancies present an aggressive course and are a significant cause of morbidity and mortality. Tumours of viral ethiology have the greatest risk in renal transplant recipients. Oncogenic effect of immunosuppressive therapy is another major risk factor of post-transplant malignancy. We report cases of three different types of malignancies developed after kidney transplantation: non-Hodgkin’s lymphoma, Kaposi’s sarcoma and germ cell testicular cancer (nonseminoma).

Opis fizyczny
  • Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Department of Onco-haematology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Department of Onco-haematology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Department of Urology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Department of Urology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • [1] Sheil AG, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major causes of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383 [PubMed]
  • [2] Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001;411:390–395[Crossref]
  • [3] Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886–1887[Crossref]
  • [4] Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002;39:E5[Crossref]
  • [5] Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71:1271–1278[Crossref]
  • [6] Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004;4:905–913[Crossref]
  • [7] Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582–1588[Crossref]
  • [8] Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 1999;354:93–99[Crossref]
  • [9] Briggs JD. Causes of death after renal transplantation. Nephrol. Dial. Transplant. 2001;16:1545–154[Crossref]
  • [10] Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD. Malignancy following renal transplantation. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:281–288
  • [11] Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923–1928[Crossref]
  • [12] Collins AJ, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(5):S1–S230
  • [13] Miao Y, Everly JJ, Gross TG, Tevar AD et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347–1359[Crossref]
  • [14] Kauffman HM, Cherikh WS, McBride MA et al. Posttransplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19:607–620[Crossref]
  • [15] Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233–1243[Crossref]
  • [16] Liebowitz, D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998; 338:1413–1421[Crossref]
  • [17] Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–230[Crossref]
  • [18] Dantal J, Hourmant M, Cantorovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens. Lancet 1998;351:623–628[Crossref]
  • [19] Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–2625[Crossref]
  • [20] Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 2002;73:1431–1439[Crossref]
  • [21] Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514–1516[Crossref]
  • [22] Campistol JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;1:581–589[Crossref]
  • [23] Kahan BD, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749–758[Crossref]
  • [24] Chapman JR, Capistol JM. Malignancy in renal transplantation: opportunities with proliferation signal inhibitors. Nephrol Dial Transplant 2007;22 (l):i1–i3[Crossref]
  • [25] Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new Mammalian target of rapamycin inhibitor. Transplantation. 2012;94(7):659–68[Crossref]
  • [26] Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative Disorders After Adult Kidney Transplant: Epidemiology and Comparison of Registry Report With Claims-Based Diagnoses. Am J Kidney Dis 2011;58(6):971–980[WoS][Crossref]
  • [27] Gotti E, Remuzzi G: Post-transplant Kaposi’s sarcoma. J Am Soc Nephrol 1997;8:130–137 [PubMed]
  • [28] Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004;77:760–762[Crossref]
  • [29] Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317–1323[Crossref]
  • [30] Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol 1997;15:2371–2377
  • [31] Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi’s sarcoma in the elderly: a randomized study of oral etoposide versus vinblastine. Cancer 1994;74:2873–2878<2873::AID-CNCR2820741021>3.0.CO;2-1[Crossref]
  • [32] Olay Dahl, Geirfinn Vagstad, Bjarne Iversen. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica 1996; 35:759–761[Crossref]
  • [33] Dean C, Bloomfield D, Holt S. The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrol Dial Transplant. 2005;20(12):2867–2868[Crossref]
  • [34] Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11:S1–86 [PubMed]
  • [35] European Best Practice Guidelines. Nephrol Dial Transplant 2002;17(4):37
  • [36] Penn I. Transmission of cancer from organ donor. Nefrologia 1995;15(3):205–213
  • [37] Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70(12):1747–1751[Crossref]
  • [38] Garrido G, Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. Transplantation 2008;85(8):S61–63[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.